Inovio Pharmaceuticals
INO
Inovio Pharmaceuticals (INO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.07
- EPS estimate
- −$0.22
- EPS surprise
- +67.70%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 12, 2026 | −$0.22 | −$0.07 | +67.70% | $0.00 | SEC |
| Q1 2026 | May 13, 2026 | −$0.35 | −$0.28 | +20.00% | $0.00 | SEC |
| Q4 2025 | Mar 12, 2026 | −$0.36 | −$0.26 | +27.37% | $0.00 | SEC |
| Q3 2025 | Nov 10, 2025 | −$0.42 | −$0.87 | −106.31% | $0.00 | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.61 | −$0.61 | +0.00% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.69 | −$0.51 | +26.30% | $65,343.00 | SEC |
| Q4 2024 | Mar 18, 2025 | −$0.84 | −$0.65 | +22.33% | $117,000.00 | SEC |
| Q3 2024 | Nov 14, 2024 | −$1.15 | −$0.89 | +22.61% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$1.10 | −$1.19 | −8.01% | $100,762.00 | SEC |
| Q1 2024 | May 13, 2024 | −$1.01 | −$1.31 | −29.28% | $0.00 | SEC |
| Q4 2023 | Mar 6, 2024 | −$1.19 | −$1.10 | +7.25% | $103,000.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$1.52 | −$1.56 | −2.63% | $388,446.00 | SEC |
| Q2 2023 | Aug 9, 2023 | −$1.74 | −$1.56 | +10.34% | $225,971.00 | SEC |
| Q1 2023 | May 10, 2023 | −$1.74 | −$1.92 | −10.34% | $114,943.00 | SEC |
| Q4 2022 | Mar 1, 2023 | −$2.02 | −$2.64 | −30.95% | $125,000.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$3.50 | −$1.80 | +48.53% | $9.2M | SEC |
| Q2 2022 | Aug 9, 2022 | −$3.72 | −$5.52 | −48.39% | $784,395.00 | SEC |
| Q1 2022 | May 10, 2022 | −$4.13 | −$4.32 | −4.65% | $199,074.00 | SEC |
| Q4 2021 | Mar 1, 2022 | −$3.79 | −$6.00 | −58.45% | $839,000.00 | — |
| Q3 2021 | Nov 9, 2021 | −$3.88 | −$3.48 | +10.22% | $291,698.00 | — |
Quarterly revenue
Frequently asked questions
When did Inovio Pharmaceuticals (INO) last report earnings?
Inovio Pharmaceuticals last reported on Aug 12, 2026, covering fiscal Q2 2026.
Did INO beat earnings estimates?
Yes. Inovio Pharmaceuticals reported EPS of −$0.07 for Q2 2026 against a −$0.22 estimate — a 67.70% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.